Sonia Saavedra

Ciprofloxacin in the treatment of urinary tract infections caused byPseudomonas aeruginosa and multiresistant bacteria

Ciprofloxacin is a new quinoline carboxylic acid derivative demonstrating better activity than other antimicrobial agents of this class (1–5). The compound is active against both gram-positive and gram-negative bacteria, particularly Enterobacteriaceae and Pseudomonas aeruginosa (6). In addition, microorganisms resistant to penicillins, cephalosporins or aminoglycosides are generally sensitive to ciprofloxacin (7). Penetration into body fluids and tissue is good after both intravenous and oral administration (8).

Treatment of urinary tract infection with norfloxacin: Analysis of cost

Twenty-five patients with urinary tract infection were treated with norfloxacin, a fluoroquinolone antibacterial with a wide spectrum of activity for an oral agent. Of 22 patients who were evaluable, 20 had complicated urinary tract infection; infection was cured in 19 patients at one week after treatment. Optimal alternative treatments were also selected in norfloxacins stead, based on each patients characteristics and the results of susceptibility testing for each isolated pathogen. Direct costs for alternative treatment ranged from

Susceptibility of aerobic gram-negative bacilli to aminoglycosides: Effects of 45 months of amikacin as first-line aminoglycoside therapy

7 to

A Severity Score Index for Clostridium difficile Infection

970. The results indicated that for those patients with suspected or proven urinary tract infection caused by multiresistant bacteria, therapy with norfloxacin may represent a cost-effective choice.